A5027983316- CAR-T cell therapy research
- Transgenic Plants and Applications
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Toxin Mechanisms and Immunotoxins
- Viral Infectious Diseases and Gene Expression in Insects
- Immune cells in cancer
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- RNA Interference and Gene Delivery
- Cancer Cells and Metastasis
- Angiogenesis and VEGF in Cancer
- Cancer, Hypoxia, and Metabolism
- Synthetic Organic Chemistry Methods
- Invertebrate Immune Response Mechanisms
- N-Heterocyclic Carbenes in Organic and Inorganic Chemistry
- vaccines and immunoinformatics approaches
- Catalytic Cross-Coupling Reactions
- Phytochemical compounds biological activities
- Insect Pest Control Strategies
- Inflammatory Biomarkers in Disease Prognosis
- Insect Resistance and Genetics
- Flavonoids in Medical Research
- Phytochemicals and Medicinal Plants
Chittaranjan National Cancer Institute
2011-2024
Immunodiagnostic Systems (Denmark)
2023
Introduction Non-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) the standard regimen for NHL, yielding complete remission (CR) rate 40-50%. Unfortunately, considerable patients undergo relapse after CR or initial treatment, resulting in poor clinical implications. Patient’s response to chemotherapy varies widely from static disease cancer...
Abstract Immune evasion within the tumor microenvironment supports malignant growth and is also a major obstacle for successful immunotherapy. Multiple cellular components soluble factors coordinate to disrupt protective immune responses. Although stromal cells are well-known their parenchymal supportive roles in cancer establishment progression, we demonstrate first time, our knowledge, that tumor-derived vascular pericytes negatively influence CD4+ T cell activation proliferation, promote...
Abstract Heterogeneity within the tumor-infiltrating lymphocytes (TIL) population limits immunotherapeutic efficacy against cancer. Between two subpopulations of exhausted CD8+ TILs (progenitor-exhausted; TPEX, terminally exhausted; TTEX), TTEX cells remain unresponsive to anti–programmed cell death protein 1(PD-1) therapy. Deciphering whether and how PD-1–resistant engage in tumor promotion could improve response immunotherapy. Here, we report that actively participate progression by...
In spite of sufficient data on Neem Leaf Glycoprotein (NLGP) as a prophylactic vaccine, little knowledge currently exists to support the use NLGP therapeutic vaccine. Treatment mice bearing established sarcomas with (25 µg/mice/week subcutaneously for 4 weeks) resulted in tumor regression or dormancy (Tumor free/Regressor, 13/24 (NLGP), 4/24 (PBS)). Evaluation CD8(+) T cell status blood, spleen, TDLN, VDLN and revealed increase cellular number. Elevated expression CD69, CD44 Ki67 cells their...
We have reported that prophylactic as well therapeutic administration of neem leaf glycoprotein (NLGP) induces significant restriction solid tumor growth in mice. Here, we investigate whether the effect such pretreatment (25µg/mice; weekly, 4 times) benefits regulation angiogenesis, an obligate factor for progression. show NLGP results vascular normalization melanoma and carcinoma bearing mice along with downregulation CD31, VEGF VEGFR2. facilitates profound infiltration CD8+ T cells within...
We have observed restriction of the murine sarcoma growth by therapeutic intervention neem leaf glycoprotein (NLGP). In order to evaluate mechanism tumor restriction, here, we analyzed microenvironment (TME) from bearing mice with NLGP therapy (NLGP-TME, in comparison PBS-TME). Analysis cytokine milieu within TME revealed IL-10, TGFβ, IL-6 rich type 2 characters was switched 1 dominance IFNγ secretion NLGP-TME. Proportion CD8+ T cells increased NLGP-TME and these were protected TME-induced...
Background: The presence of Tregs in tumors is associated with compromised tumor-specific immune responses and has a clear negative impact on survival cancer patients. Thus, downregulation considered as promising immunotherapeutic approach. We have reported previously that neem leaf glycoprotein (NLGP) prophylaxis restricts tumor growth mice by activation. In continuation, here, involvement NLGP the modulation association restriction investigated. Results: downregulates CD4+CD25+Foxp3+...
Abstract Background A water-soluble ingredient of mature leaves the tropical mahogany ‘Neem’ ( Azadirachta indica ), was identified as glycoprotein, thus being named ‘Neem Leaf Glycoprotein’ (NLGP). This non-toxic leaf-component regressed cancerous murine tumors (melanoma, carcinoma, sarcoma) recurrently in different experimental circumstances by boosting prime antitumor immune attributes. Such immunomodulation, aid cytotoxic T cell (T c )-based annihilation tumor cells. study focused on...
Therapy with neem leaf glycoprotein (NLGP) inhibits murine B16-melanoma in vivo and improves survivability. Studies on tumor-microenvironment (TME) from NLGP treated mice (NLGP-TME) suggests that anti-tumor effect is directly associated enhanced CD8+T cell activity, dominance of type 1 cytokines/chemokine network downregulation suppressive cellular functions. NLGP-TME educated cells showed higher perforin granzymeB expression greater vitro cytotoxicity against B16 melanoma. These...
Carcinoembryonic antigen (CEA) is one of the promising tumor antigens mainly associated with carcinoma colon, lung, breast, etc. and received wide attention for cancer immunotherapy. Neem leaf glycoprotein (NLGP), an effective immunomodulator, able to generate humoral cellular immune responses in murine models. We have generated a monoclonal antibody (mAb) against NLGP by fusing NLGP-immunized mice splenocytes nonsecretory myeloma cells. A highly anti-NLGP mAb secreting clone (1C8; IgG2a...
Neem Leaf Glycoprotein (NLGP) is a natural immunomodulator, have shown sustained tumor growth restriction as well angiogenic normalization chiefly by activating CD8+ T cells. Here, we investigated the direct role of NLGP regulator microenvironmental hypoxia and associated vascular endothelial factor (VEGF) production. We observed significant reduction in VEGF level both vivo murine vitro cancer cells (B16Mel, LLC) macrophages after treatment. Interestingly, mediated downregulation or within...
Neem leaf glycoprotein (NLGP), a natural immunomodulator, attenuates murine carcinoma and melanoma metastasis, independent of primary tumor growth alterations in basic cellular properties (cell proliferation, cytokine secretion, etc.). Colonization event invasion-metastasis cascade was primarily inhibited by NLGP, with no effect on metastasis-related invasion, migration, extravasation. High infiltration interferon γ (IFN-γ)-secreting cytotoxic CD8+ T cells [CD44+, CD69+, GranB+, IFN-γ+,...
<p>Contains supplementary figure S1, S2, S3, S4, S5 and S6.</p>